Targets › GARP
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout May 2027.
Open in Phaseline: the race on GARP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ohio State University Comprehensive Cancer Center | Anti-GARP Chimeric Antigen Receptor-T Cells Anti-GARP CAR-T cell therapy | GARP | Phase 1 | Recurrent Malignant Glioma | May 2027 |
Recurrent Malignant Glioma (1)
other (1)
Ohio State University Comprehensive Cancer Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.